NCT03462576View on ClinicalTrials.gov

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17

TerminatedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

July 15, 2019

Study Completion Date

July 15, 2019

Conditions
Decompensated Cirrhosis
Interventions
COMBINATION_PRODUCT

Methacetin Breath Test

A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

DRUG

Emricasan

Investigational drug for NASH treatment in Main Conatus protocol

DRUG

Placebo oral capsule

Placebo versus emricasan in Conatus NASH treatment trial

Trial Locations (1)

34211

Florida Digestive Health Specialists Research Institute, Lakewood Rch

Sponsors
All Listed Sponsors
collaborator

Conatus Pharmaceuticals Inc.

INDUSTRY

lead

Meridian Bioscience, Inc.

INDUSTRY

NCT03462576 - Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17 | Biotech Hunter | Biotech Hunter